1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aarti Drugs Limited

Aarti Drugs Limited

AARTIDRUGS.NS
Aarti Drugs LimitedIN flagNational Stock Exchange of India
381.70
INR
+3.30
- -
34.84BMarket Cap

Total Valuation

Aarti Drugs Limited carries a market capitalization of 34.84B, placing it among publicly traded companies globally. Its enterprise value stands at 34.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap34.84B
Enterprise Value34.71B

Share Statistics

Aarti Drugs Limited currently has 91.27M shares outstanding.

Shares Outstanding91.27M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Aarti Drugs Limited trades at a trailing price-to-earnings ratio of 14.97. The price-to-sales ratio is 1.14, and the price-to-book ratio stands at 31.98.

PE Ratio14.97
PS Ratio1.14
PB Ratio31.98
P/TBV Ratio1.90
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Aarti Drugs Limited trades at an EV/EBITDA multiple of 14.33 and an EV/FCF ratio of 111.40. The EV/Sales ratio of 1.35 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.33 provides insight into valuation relative to core operating earnings.

EV / Sales1.35
EV / EBITDA14.33
EV / EBIT14.33
EV / FCF111.40

Financial Position

Aarti Drugs Limited maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 37.22, indicating elevated leverage, while an interest coverage ratio of 7.19 demonstrates adequate ability to service its debt obligations.

Current Ratio1.59
Quick Ratio0.03
Debt / Equity37.22
Debt / EBITDA2.38
Interest Coverage7.19

Financial Efficiency

Aarti Drugs Limited posts a return on equity of 27.40 and a return on invested capital of 10.89.

Return on Equity (ROE)27.40
Return on Assets (ROA)7.23
Return on Invested Capital (ROIC)10.89
Return on Capital Employed (ROCE)17.29
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.36

Taxes

Over the trailing twelve months, Aarti Drugs Limited has paid 159.60M in income taxes, reflecting an effective tax rate of 7.57.

Income Tax159.60M
Effective Tax Rate7.57

Stock Price Statistics

Aarti Drugs Limited's stock has declined approximately -17.73707% over the past 52 weeks. The 50-day moving average sits at 369.73, while the 200-day moving average is 414.00.

Beta (5Y)N/A
52-Week Price Change-17.73707%
50-Day Moving Average369.73
200-Day Moving Average414.00
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Aarti Drugs Limited generated 25.65B in revenue and converted that into 1.95B in net income, yielding earnings per share of 21.36. EBITDA reached 2.42B, while operating income came in at 2.42B.

Revenue25.65B
Gross Profit9.47B
Operating Income2.42B
Pretax Income2.11B
Net Income1.95B
EBITDA2.42B
EBIT2.42B
Earnings Per Share (EPS)21.36

Balance Sheet

Aarti Drugs Limited holds 242.80M in cash and equivalents against 5.77B in total debt, resulting in a net debt position of 5.68B. Total book value stands at 912.70M, with working capital of 5.46B providing operational flexibility.

Cash & Cash Equivalents242.80M
Total Debt5.77B
Net Debt5.68B
Equity (Book Value)912.70M
Book Value Per Share10.00
Working Capital5.46B

Margins

Aarti Drugs Limited operates with a gross margin of 36.90, reflecting its pricing power and cost economics. The operating margin of 9.44 and net profit margin of 7.60 provide insight into operational efficiency.

Gross Margin36.90
Operating Margin9.44
Pretax Margin8.22
Profit Margin7.60
EBITDA Margin9.44

Stock Splits

Aarti Drugs Limited's most recent stock split took place on September 30, 2020 with a 1:4 split ratio.

Last Split Date9/30/2020
Split Ratio1:4

Scores

Aarti Drugs Limited posts an Altman Z-Score of 2.82, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.82